Plain-English translation of NCT06578247 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called , when combined with standard and taken as an ongoing treatment, can help people with newly diagnosed acute myeloid leukemia (AML) live longer. Participants will either receive the medication alongside , alone with a placebo pill, or the medication during initial treatment followed by a placebo. The study is comparing survival outcomes across all three groups.
Acute myeloid leukemia is a serious blood cancer, and while standard is the current treatment, doctors want to see if adding this medication can improve how long patients survive and improve their chances of getting better.
You will first receive standard treatment at a hospital or clinic. After that is complete, you will take either the new medication, a placebo pill, or the medication followed by a placebo pill—depending on which group you are randomly assigned to—once daily by mouth for up to 36 cycles (about 2 years). You will have regular clinic visits and blood tests to monitor your health and how well the treatment is working. Your doctor will track your overall survival and how you are responding to treatment throughout the trial.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States